MAPT and Alzheimer disease: In case of doubt between VaD or mixed AD–CVD pathology in dementia patients, the determination of CSF Aβ1-42, T-tau, and P-tau181 levels is of help to confirm or exclude the AD component in the pathophysiology of the dementia syndrome [58].